On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
On February 4, 2025, Herbert Simon, age 90, a member and Chaiman Emeritus of the Board of Directors (the “Board”) of Simon Property Group, Inc. (the “Company”) notified the Company that he is retiring from the Board, including his position as Chairman Emeritus, effective as of such date.
On February 27, 2024, Mr. Keijiero Varela tendered his resignation, effective March 12, 2024 (the “Effective Date”), as Director of The Cannaisseur Group, Inc. (the “Company”), to pursue other business opportunities.
On December 4, 2024, Mr. Harold "Butch" Woolfolk tendered his resignation, effective December 13, 2024 (the "Effective Date"), as Director of The Cannaisseur Group, Inc. (the "Company"), to pursue other business opportunities.
On February 6, 2025, Sabre Corporation (“Sabre”) announced that Karl Peterson will be retiring from the Board, as well as from all Board committees on which he sits, effective immediately prior to Sabre’s 2025 Annual Meeting of Stockholders, which is scheduled to be held on April 23, 2025.
Departed
Angus C. Russell
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Chris Nolet
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Vlad Coric
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Julian S. Gangolli
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Jill Beraud
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Olivia C. Ware
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Mark J. Foley
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Carey O’Connor Kolaja
director
Revance Therapeutics, Inc.
Effective
2025-02-06
Successor
Jeffery A Bedard
Filed
February 6, 2025, 6:59 PM ET
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
Departed
Sarah Payne
Chief Human Resources Officer
HEIDRICK & STRUGGLES INTERNATIONAL INC
Effective
2025-03-31
Filed
February 6, 2025, 6:59 PM ET
On January 27, 2025, the Company agreed with Sarah Payne that she will transition from the position of Chief Human Resources Officer to an advisory role, effective March 31, 2025.
Departed
Tammy M. Finley
Executive Vice President, General Counsel and Corporate Secretary
Tammy M. Finley, the Company’s Executive Vice President, General Counsel and Corporate Secretary, will be leaving the organization and beginning her retirement.
Departed
Stephen Karp
General Counsel
Markforged Holding Corp
Effective
2025-03-03
Filed
February 6, 2025, 6:59 PM ET
On February 4, 2025, Stephen Karp informed the Board of Directors (the “Board”) of Markforged Holding Corporation (the “Company”) that he would resign from his position as General Counsel of the Company, effective March 3, 2025, to pursue an opportunity outside of the Company.
On January 31, 2025, Bonnie S. Van Etten, Vice President, Controller and Chief Accounting Officer, notified the Company of her intent to conclude service with the Company in early March of 2025.
On January 20, 2025, Yingda Wu, a member of the Board of Directors of Kuber Resources Corp. (the “Company”), tendered his resign from the Company's Board of Directors, effective January 20, 2025.
Michael Gordon ceased serving as Chief Operating Officer and Chief Financial Officer effective as of January 31, 2025.
Departed
Zachary Rome
Director
PaxMedica, Inc.
Effective
2025-01-31
Filed
February 6, 2025, 6:59 PM ET
On January 31, 2025, Zachary Rome resigned from the Board for personal reasons, effective immediately.
Departed
Stephen D. Sheldon
Chief Financial Officer and Chief Operational Officer
PaxMedica, Inc.
Effective
2025-01-31
Filed
February 6, 2025, 6:59 PM ET
On January 31, 2025, Stephen D. Sheldon, chief financial officer and chief operational officer of PaxMedica, Inc., a Delaware corporation (the “Company”), provided notice of his resignation as an executive officer of the Company, effective immediately.
Michael Maniscalco, the Company’s Chief Technology Officer, has informed the Company that he is resigning, effective January 31, 2025, to pursue other opportunities.
On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
Departed
Jaydriane Panis
Director
Virpax Pharmaceuticals, Inc.
Effective
2025-02-03
Successor
Charn Deol
Filed
February 6, 2025, 6:59 PM ET
Jaydriane (Jay) Panis, who resigned from the Board on February 3, 2025.
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
Departed
Christopher A. Coughlin
Executive Vice President, President of Industrial Motion
On February 3, 2025, Christopher A. Coughlin, Executive Vice President, President of Industrial Motion, of the Company notified the Company of his intention to retire by the end of December 2025.
On January 31, 2025, William A. Kozy informed the Board of Directors (the "Board") that he will retire as a director, effective on the date of The Cooper Companies, Inc.'s (the "Company's") next Annual Meeting of Stockholders in April 2025 (the "Annual Meeting").
Departed
Busy Burr
Director
Maverick Merger Sub 2, LLC
Effective
2025-01-31
Filed
February 5, 2025, 6:59 PM ET
On January 31, 2025, Busy Burr notified the Board of Directors (the “Board”) of Mr. Cooper Group Inc. (the “Company”) that she has decided to resign from the Board effective immediately.
On January 30, 2025, Xometry, Inc. (the “Company”) and Matt Leibel, the Company’s Chief Technology Officer, mutually agreed that Mr. Leibel would separate from his role at the Company effective as of February 5, 2025 (the “Effective Date”).
On February 5, 2025, the Company and Jeff Dossett, the Company’s Chief Revenue Officer, announced that Mr. Dossett intends to retire and will depart the Company effective February 21, 2025.
Departed
Mark Rothera
President and Chief Executive Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed
Michael Faerm
Chief Financial Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed
Roger Pomerantz
Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Darrel P. Cohen
Chief Medical Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed
Thomas E. Darcy
Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Mark Rothera
Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Ivor Royston
Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed
Flavia Borellini
Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.